|
Available Now!
2014 NIH SBIR & STTR Omnibus Grant Solicitation for Small Businesses |
Are you a small business in need of funding to advance your novel cancer technology?
The 2014 SBIR and STTR Omnibus Grant Solicitation of the NIH is now live and the National Cancer Institute’s (NCI) budget for the program is increasing. Funding from the NCI Small Business Innovation Research & Small Business Tech Transfer (SBIR & STTR) Programs can help you advance your technology towards commercialization and can also help spark investor interest in your business.
The next application due date is April 5, 2014. We encourage you to start preparing your application and are happy to provide feedback on your project. If you’d like to take advantage of this opportunity, please email the NCI SBIR program director listed in your relevant technology area. Also be sure to check that all of your required registrations are complete. It’s never too early to start the registration process.
New changes in the 2014 Omnibus Solicitation include additional provisions of the 2011 SBIR & STTR Reauthorization Act, so please read the solicitations carefully.
- Applicants may now switch between SBIR & STTR Programs. Those who previously were funded under an STTR Phase I award are now eligible to apply for an SBIR Phase II award, and vice versa.
- Small business concerns that are majority-owned by multiple venture capital operating companies (VCOCs), hedge funds and/or private equity firms are eligible to apply to the NIH SBIR program. View frequently asked questions on VC participation.
View the Application Guide for NIH and Other PHS Agencies for more information on preparing and submitting SBIR & STTR applications.
|
 |
|
|
PHS 2014-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
Receipt Dates: April 5, 2014; August 5, 2014; December 5, 2014PHS 2014-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
Receipt Dates: April 5, 2014; August 5, 2014; December 5, 2014
Applications proposing innovative cancer-related technologies, with strong commercial potential, in a wide range of topic areas, are invited through the Omnibus Solicitations. Please visit the Research Topics of Interest page on the SBIR website to view the list of portfolio areas.
NCI particularly encourages applications in the following
- Development of Low Cost Technologies for Global Health
- Development of Companion Diagnostics
- Vaccine Development for Cancer Prevention
- Novel Technologies to Address “Undruggable” Drug Targets
- New Technologies to Assess Tissue-Based Markers of Tumor Death and Mitochondrial Stress in Response to Therapy
|
|
|
|
|
|
|
|
Additional funding opportunities include:
- PA-12-196, Innovative Health Information Technology for Broad Adoption by Healthcare Systems and Consumers (SBIR) (R44)
Receipt dates: April 5, 2014; August 5, 2014; December 5, 2014
- PA-13-140 Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44)
Receipt dates: April 5, 2014; August 5, 2014; December 5, 2014; April 5, 2015; August 5, 2015; December 5, 2015
- PAR-13-327 Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (SBIR-IMAT) (R43/R44)
Receipt dates: May 28, 2014; November 4, 2014; May 27, 2015; November 4, 2015; May 27, 2016
|
|
|
|
|
|
Who is Eligible to Apply:
U.S. small business concerns:
- SBIR & STTR: Small business concerns that are more than 50% directly owned and controlled by one or more individuals, other business concerns, or any combination of these; OR be a joint venture in which each entity in the joint venture must meet certain requirements.
- SBIR only: Small business concerns that are more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these.
Benefits of Applying:
- SBIR & STTR funding can be a leveraging tool to help attract additional funding from other third-party investors.
- Awards are not loans; no repayment is required.
- SBIR & STTR funding is non-dilutive capital (i.e., an award does not impact the company’s stock or shares in any way). Intellectual property rights to technologies developed under these programs are retained by the small business concern.
- SBIR & STTR awards provide recognition, verification, and visibility.
Questions?
Contact the NCI SBIR Development Center at NCIsbir@mail.nih.gov, or a Program Director with the relevant area of expertise, http://sbir.cancer.gov/contact_us.asp.
Please visit http://sbir.cancer.gov/ to learn more about the NCI SBIR & STTR Programs. |
The SBIR & STTR Programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. The SBIR & STTR Programs are government set-aside programs for domestic small businesses to engage in research and development that has the potential for commercialization and public benefit.Sign up to receive updates about
SBIR & STTR funding opportunities at
sbir.cancer.gov |
|
